HBe VLP
Escherichia Coli.
Sterile Filtered clear solution.
Protein is >95% pure as determined by 10% PAGE (coomassie staining).
Description
Recombinant hepatitis B Virus-e Virus Like Particle is produced in E.coli andhaving a molecular mass of approximately 18kDa. The HBe VLP is fused to a His tag and purified by proprietary chromatographic technique.
Product Specs
Hepatitis B virus (HBV) is a major cause of human liver disease. Chronic HBV infection can lead to serious complications like liver cancer and cirrhosis. The hepatitis B e antigen (HBeAg) is detectable in the bloodstream during active HBV infection. A positive HBeAg result suggests a higher risk of HBV transmission and is used to monitor the effectiveness of HBV treatment. Conversely, the presence of antibodies against HBeAg (anti-HBeAg) typically indicates an active HBV infection nearing its final stages, with a significantly reduced risk of transmission. HBe virus-like particles (VLPs) are utilized in competitive assays to detect anti-HBeAg in individuals with HBV infection.
Recombinant hepatitis B virus e antigen virus-like particles (HBe VLPs) are produced in E. coli, resulting in a molecular mass of approximately 18 kDa. These VLPs are fused to a His tag, facilitating purification through a proprietary chromatographic technique.
The product appears as a sterile-filtered, clear solution.
The HBe VLP protein solution is supplied in phosphate-buffered saline (PBS) containing 0.05% sodium azide (NaN3) as a preservative.
For short-term storage (2-4 weeks), the product should be stored at 4°C. For extended storage, it is recommended to store the product frozen at -20°C. The addition of a carrier protein (0.1% HSA or BSA) is advised for long-term storage. Avoid repeated freeze-thaw cycles to maintain product integrity.
The purity of the HBe VLP protein is greater than 95%, as determined by 10% SDS-PAGE analysis with Coomassie blue staining.
The HBe VLP protein is suitable for use in various applications, including enzyme-linked immunosorbent assays (ELISA) and lateral flow assays.
Escherichia Coli.
Product Science Overview
Hepatitis B Virus-e (HBV-e) Virus Like Particles (VLPs) are non-infectious, self-assembled protein structures that mimic the native virus without containing viral genetic material. These VLPs are produced using recombinant DNA technology, where the genes encoding viral proteins are expressed in host cells such as yeast, bacteria, or mammalian cells . VLPs are classified based on the viral proteins they contain and their structural resemblance to the native virus .
HBV-e VLPs are composed of the hepatitis B surface antigen (HBsAg) proteins, which spontaneously assemble into particles resembling the outer shell of the hepatitis B virus . These particles are highly immunogenic, meaning they can elicit a strong immune response in the host without causing disease . The primary function of HBV-e VLPs is to serve as a vaccine component, providing immunity against hepatitis B infection by stimulating the production of antibodies against HBsAg .
The mode of action of HBV-e VLPs involves the activation of the immune system. When administered as a vaccine, these particles are recognized by the immune system as foreign entities, leading to the activation of antigen-presenting cells (APCs) such as dendritic cells . These APCs process the VLPs and present the HBsAg peptides to T cells, which in turn activate B cells to produce specific antibodies against HBsAg . This immune response provides protection against future hepatitis B infections by neutralizing the virus upon exposure .
The production and use of HBV-e VLPs as vaccines are regulated by various health authorities, including the World Health Organization (WHO) and national regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) . These regulatory bodies ensure that the vaccines are safe, effective, and of high quality through rigorous testing and evaluation processes . The recombinant DNA technology used in the production of HBV-e VLPs is also subject to strict guidelines to prevent contamination and ensure consistency in vaccine batches .
